Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance

Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance

Urokinase plasminogen activator receptor (uPAR), a member of the lymphocyte antigen 6 protein superfamily, is overexpressed in different types of cancers and plays an important role in tumorigenesis and development. In this study, we successfully targeted uPAR by CRISPR/Cas9 system in two human canc...

Full description

Bibliographic Details
Main Authors: Kun Wang, Zi-Hao Xing, Qi-Wei Jiang, Yang Yang, Jia-Rong Huang, Meng-Ling Yuan, Meng-Ning Wei, Yao Li, Sheng-Te Wang, Kun Liu, Zhi Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Oncology
Subjects:
cancer
uPAR
CRISPR/Cas9
malignancy
drug resistance
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00080/full
Description
Summary:Urokinase plasminogen activator receptor (uPAR), a member of the lymphocyte antigen 6 protein superfamily, is overexpressed in different types of cancers and plays an important role in tumorigenesis and development. In this study, we successfully targeted uPAR by CRISPR/Cas9 system in two human cancer cell lines with two individual sgRNAs. Knockout of uPAR inhibited cell proliferation, migration and invasion. Furthermore, knockout of uPAR decreases resistance to 5-FU, cisplatin, docetaxel, and doxorubicin in these cells. Although there are several limitations in the application of CRISPR/Cas9 system for cancer patients, our study offers valuable evidences for the role of uPAR in cancer malignancy and drug resistance.
ISSN:2234-943X

Similar Items